An activation of the mTOR pathway independently of the PI3K/AKT pathway was also detected, suggesting that inhibiting both PI3K and mTOR (with the PI-103 inhibitor or similar), combined with the ABL inhibitor imatinib, could be a potential therapeutic avenue for Ph+ pre-B ALL. Here, PIK3CD is linked to acute lymphoblastic leukemia.